Experience

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Revance Therapeutics, Inc. of its common stock for up to an aggregate amount of $125 million. Based…

Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its ordinary shares represented by American depositary shares for up to an…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by MPH Acquisition Holdings LLC, a wholly owned subsidiary of MultiPlan…

Davis Polk advised the joint book-running managers in connection with a $216.2 million public offering of 5,750,000 shares of common stock by NanoString Technologies, Inc., which…

    Davis Polk advised the joint book-running managers and representatives to the underwriters in connection with the approximately $200 million follow-on public offering of…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Hologic, Inc. of $950 million aggregate principal amount of its…

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk is advising Amwell on its agreement to form a multi-year, strategic partnership with Google Cloud to deliver transformative telehealth solutions across the global healthcare…

Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of 5,500,000 American Depositary Shares of BioNTech SE. In addition,…